Application of luteolin in preparation of ovarian senescence resistance medicines

A technology of luteolin and ovarian aging, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical preparations containing active ingredients, etc., to achieve significant proliferation, expand the scope of application, and increase the secretion level

Inactive Publication Date: 2013-05-08
INST OF BOTANY JIANGSU PROVINCE & CHINESE ACADEMY OF SCI
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the application of luteolin in the preparation of anti-ovarian aging drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of luteolin in preparation of ovarian senescence resistance medicines
  • Application of luteolin in preparation of ovarian senescence resistance medicines
  • Application of luteolin in preparation of ovarian senescence resistance medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] [Example 1] Proliferation of luteolin on isolated ovarian granulosa cells (MTT method)

[0017] Female rats aged 22-27 days were killed by cervical dislocation after 48 hours of routine feeding. The bilateral ovaries of the rats were aseptically removed, and the ovaries were crushed to release granulosa cells. They were treated with 2 mL of DMEM-F12 containing penicillin and streptomycin. Dilute in culture medium and gently pipette to disperse into single cells. Pellet cells were collected by centrifugation. A certain concentration of cell suspension was inoculated in a 24-well plate, 80 μl per well, and 120 μl of culture medium was added to each well to adjust the cell density to 200 μl / well, and 6 parallel wells were set up for each group. Put it in 5% CO 2 Cultivate in the incubator for 24h. Take CO 2 The granule cell suspension was cultivated in the incubator for 24 hours, and each well was successively added with cadmium chloride of modeling concentration and d...

Embodiment 2

[0021] [Example 2] The effect of luteolin on the estrogen and progesterone secretion of isolated ovarian granulosa cells (radioimmunization method)

[0022] Female rats aged 22-27 days were killed by cervical dislocation after 48 hours of routine feeding. The bilateral ovaries of the rats were aseptically removed, and the ovaries were broken to release granulosa cells. They were treated with 2ml of DMEM-F12 containing penicillin and streptomycin. Dilute in culture medium and gently pipette to disperse into single cells. Pellet cells were collected by centrifugation. A certain concentration of cell suspension was inoculated in a 24-well plate, 80 μl per well, and 120 μl of culture medium was added to each well to adjust the cell density to 200 μl / well, and 6 parallel wells were set up for each group. Put it in 5% CO 2 Cultivate in the incubator for 24h. Take CO 2 The granule cell suspension was cultivated in the incubator for 24 hours, each well was successively added with ...

Embodiment 3

[0026] [Example 3] Effect of luteolin on the secretion of estrogen and progesterone in natural aging rats (radioimmunization method)

[0027] Adopt the pre-aging model of natural aging. Select 14-month-old female SD rats with a body weight of (270±30) g. After the animals are fed for one week, do vaginal cytology smears and observe 4 estrous cycles continuously. Vaginal cytology shows that the estrous cycle is prolonged and then continues to be in estrus , Repeated pseudo-pregnancy cell phase, as a successful model of female aging. Natural aging rats were randomly divided into model group, luteolin (10mg / kg, 30mg / kg, 50mg / kg) group and positive drug group, with 10 rats in each group, and another 11 4-month-old female rats were used as The normal control group was intragastrically administered once a day, and the normal control group and the model group were given equal volumes of normal saline. After 30 days of continuous administration, blood was collected from the orbital v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of luteolin in preparation of ovarian senescence resistance medicines. The luteolin has obvious effects in treatment of multiple ovarian regression diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovary failure or climacteric syndrome. The luteolin is prepared into oral medicines, transdermal delivery medicines or injection medicines for treating the ovarian regression diseases.

Description

technical field [0001] The invention relates to the medical use of luteolin, that is, the application of luteolin in drugs for effectively treating various ovarian recession diseases. Background technique [0002] Ovarian aging is a complex biological process with multiple factors interacting and gradually accumulating. The main cause of ovarian aging is the decline in the number of follicles as the number of follicles passes by. The accumulation of metabolites in the body changes the microenvironment of the ovary, such as damage to follicles by free radicals and end products of glycation, and mitochondrial DNA mutations, With the continuous accumulation of factors such as telomere shortening, the quality of remaining follicles is also reduced; the expression and function of a series of genes in the ovary are changed, and the secretion of H-P-O axis (Hypothalamus-Pituitary-Ovary Axis, hypothalamus-pituitary-ovary axis) hormones Finely regulate ovarian function. The decline...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P15/08A61P15/00A61P15/12
Inventor 吕晔韦敏马红
Owner INST OF BOTANY JIANGSU PROVINCE & CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap